Key facts
- This page summarizes PERCEPTIVE ADVISORS LLC's Form 4 filing for Nautilus Biotechnology, Inc. (NAUT).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 17 Jun 2024, 18:02.
PERCEPTIVE ADVISORS LLC - 14 Jun 2024 Form 4 Insider Report for Nautilus Biotechnology, Inc. (NAUT)
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- NAUT
- Reported as of
- 14 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 17 Jun 2024, 18:02:16 UTC
- Prior SEC filing
- 19 Nov 2024
- Next SEC filing
- 27 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Joseph Edelman - for Perceptive Advisors LLC, By: Joseph Edelman, its managing member
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
PERCEPTIVE ADVISORS LLC filed Form 4 for Nautilus Biotechnology, Inc. (NAUT) on 17 Jun 2024.
Change
- Previous filing in this sequence was filed on 19 Nov 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NAUT
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +45,000
- Change %
- Price
- $0.000000
- Shares after
- 45,000
- Date
- 14 Jun 2024
- Ownership
- See Footnotes
- Underlying class
- Common Stock
- Underlying amount
- 45,000
- Exercise price
- $2.56
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Subject to the continuous status of Mr. Altman as a "Service Provider" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of the grant on the same day of the month as such grant date.
Footnote F2
Consists of options to purchase shares of the Issuer's common stock awarded to Michael Altman in connection with his role as a member of the Issuer's Board of Directors. Mr. Altman is affiliated with Perceptive Advisors LLC (the "Advisor"). The Advisor may be deemed to have an indirect pecuniary interest in the options to purchase common stock of the Issuer reported herein because the Advisor has the right to receive the director compensation provided in respect of Mr. Altman's board service through a partial management fee offset.
Footnote F3
Joseph Edelman is the managing member of the Advisor. The Advisor serves as the investment manager of Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Each of Mr. Edelman, the Master Fund and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of the securities reported on this form, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman, the Master Fund or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.